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Background: There is insufficient evidence of the cost-effectiveness of Chronic Obstructive Pulmonary Disease
(COPD) Disease Management (COPD-DM) programs. The aim of this review is to evaluate the economic impact of
COPD-DM programs and investigate the relation between the impact on healthcare costs and health outcomes. We
also investigated the impact of patient-, intervention, and study-characteristics.
Methods: We conducted a systematic literature review to identify cost-effectiveness studies of COPD-DM. Where
feasible, results were pooled using random-effects meta-analysis and explorative subgroup analyses were
performed.
Results: Sixteen papers describing 11 studies were included (7 randomized control trials (RCT), 2 pre-post, 2
case–control). Meta-analysis showed that COPD-DM led to hospitalization savings of €1060 (95% CI: €2040 to €80)
per patient per year and savings in total healthcare utilization of €898 (95% CI: €1566 to €231) (excl. operating
costs). In these health economic studies small but positive results on health outcomes were found, such as the
St Georges Respiratory Questionnaire (SGRQ) score, which decreased with 1.7 points (95% CI: 0.5-2.9). There was
great variability in DM interventions-, study- and patient-characteristics. There were indications that DM showed
greater savings in studies with: severe COPD patients, patients with a history of exacerbations, RCT study design,
high methodological quality, few different professions involved in the program, and study setting outside Europe.
Conclusions: COPD-DM programs were found to have favourable effects on both health outcomes and costs, but
there is considerable heterogeneity depending on patient-, intervention-, and study-characteristics.
Keywords: Chronic obstructive pulmonary disease, Efficiency, Cost-effectiveness, Costs, Meta-analysis, Review,
Integrated care, Disease management, COPD, Economic evaluationBackground
Traditional healthcare for Chronic Obstructive Pulmo-
nary Disease (COPD) focuses on pharmacotherapy to
reduce symptoms and prevent exacerbations whereas
patients are usually treated by a single healthcare profes-
sional, commonly the general practitioner or the respi-
ratory physician. However, COPD is a multi-component
disease with a wide range of comorbidities [1]. Essential* Correspondence: boland@bmg.eur.nl
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reproduction in any medium, provided the ordeterminants in improving health outcomes of COPD
patients are behavioural changes in physical activity, diet
and smoking. Thus, assessment and treatment of the air-
ways alone is evidently insufficient in the care of COPD
patients [2,3]. COPD requires an integrated, tailor-made
approach. Such integrated approach mostly asks for a
transformation in the healthcare organization from acute
and reactive to proactive and planned healthcare. How-
ever, these behavioural and organizational changes require
time and cannot be reached by implementing a single
intervention. Instead, a set of organizational, professional-,
and patient-oriented interventions is required for a suc-
cessful change in organizational structure and processesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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agement (DM) is such an approach and is seen as a solu-
tion to tackle the challenges posed by COPD.
Although DM programs are generally believed to be
cost-effective, the available evidence is inconclusive. Se-
veral systematic reviews have evaluated the effects of
COPD-DM [4-9]. However, they gave little insight into
the economic consequences. Only the review of Steuten
et al. [8], which searched studies between 1995 and
2007, included 3 studies which evaluated cost data.
Since then, several studies focusing on DM and cost-
effectiveness have been published. Furthermore, the re-
view of De Bruin et al. [9], which searched for DM stud-
ies between 2007 and 2009, included 5 studies which
evaluated cost data of COPD-DM programs, but did not
include the studies before 2007 and after 2009. Further-
more, these two systematic reviews did not perform a
meta-analysis on costs and effects. [4-9]In addition, little
is known on the key elements of DM programs that are
able to affect the outcomes and cost of COPD in a par-
ticular setting [5,10]. The great variation in DM inter-
ventions, study characteristics, patient characteristics,
quality of study and a limited recognition of the impact
of these differences on the outcomes are the reasons that
evidence on cost-effectiveness of the DM programs pro-
vides limited support to decision makers [10]. The aim
of this review is to evaluate the economic impact of
COPD-DM programs and investigate the relation be-
tween the impact on healthcare costs and health out-
comes. We also investigate whether this impact depends
on intervention-, study-, and patient-characteristics.
Methods
Search strategy and selection criteria
A systematic electronic literature search for economic
evaluations of COPD-DM was performed in Medline,
the economic evaluation database of the UK National
Health System (NHS-EED) and the EUROpean Network
of Health Economic Evaluation Database (EURONHEED).
The search was restricted to the English, German and
Dutch language, but there were no restrictions to dates.
All databases were searched on 21 July 2011.
For the selection of the search terms, we firstly identi-
fied the key elements of DM. There are several defini-
tions of DM available in the literature [11]. A short
overview of definitions published in the last decade is
shown in Additional file 1. Most definitions have eight
elements in common that characterize DM, which are:
1) focusing on a target group of patients with a chronic
condition, 2) multi-interventions developed for patient,
healthcare provider and/or organization, 3) pro-active,
planned healthcare, 4) evidence based/according to
guideline, 5) self- management, 6) multidisciplinary team,
7) monitoring of performance and 8) supporting clinicalinformation systems [11-18]. Furthermore, DM programs
are often based on Wagner’s Chronic Care Model (CCM)
[19], especially in Europe (EU). The CCM includes six in-
terrelated components that are essential for improving
chronic care. There are four elements at the micro level
emphasizing interactions between patients, providers and
community: 1) self-management, to empower and prepare
patients to manage their disease (e.g. patient education,
counselling to improve self-efficacy); 2) delivery system
design, that assures the delivery of effective and efficient
clinical and behavioural care (e.g. systematic and pro-
active follow-up of patients); 3) decision support, to
promote the use of evidence-based clinical care (e.g. elec-
tronic guidelines incorporated in information system); and
4) clinical information system, to assure access to timely,
relevant data about patients (e.g. electronic patient rec-
ord). One element at the meso level: 5) community, to link
community and healthcare delivery. And one element at
the macro level: 6) organizational support, to consider the
policy and financing context. An indicated list with DM
interventions grouped per CCM component is presented
in Additional file 2. Overall, DM requires a change in rou-
tine care delivery for a prolonged period of time and DM
programs often focus on the entire spectrum of seve-
rity of a disease and its complications, including often
(secondary) prevention as well.
Besides the elements of DM, the search terms included
descriptions of COPD, cost(s) and economic evaluation.
The complete search strategy can be found in Additional
file 3. Additional studies were sought by hand searching
the reference list of reviews on economic evaluation of
DM found in the literature search. The titles, keywords,
abstracts and papers were screened to assess whether
the study met the following inclusion criteria:
1. At least some of the patients had COPD and the
results of the subgroup of COPD patients were
presented separately;
2. The study included at least two DM interventions
from the list presented in Additional file 2;
3. The study was an original empirical research paper
excluding therefore, review, methodological and
modelling studies;
4. The study reported both costs and effects;
5. The DM program had a minimum duration of 12
months (intensive + maintenance phase);
6. The comparator was usual care or no-intervention.
Potentially relevant studies retrieved from the elec-
tronic searches were identified by two reviewers (MB
and AT) based on the predetermined inclusion criteria
in a two-step procedure: 1) title, keywords, and abstract,
2) a brief screening of intervention, outcomes and costs.
When disagreement of the two researchers could not be
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ted to reach consensus.
Quality assessment, risk of bias and data analyses
We developed a check-list to assess the methodologi-
cal quality of the studies based on the check-list of
Drummond et al. [20] and the health technology assess-
ment disease management instrument of Steuten et al.
[21]. The former is used to assess the quality of econo-
mic evaluation studies in general and the latter is used
to assess the methodological quality of DM evaluations
specifically. The combined list assessed the strength and
weaknesses of the studies on 7 key elements, each of
which contains three or more items (see results section
for the entire list) with a yes/no response option. The
total quality score of a study is calculated as the sum of
items with a positive assessment as a percentage of the
number of applicable items. Hence, the maximum score
is 100%.
We assessed the risk of bias of the individual studies
according to the Cochrane Handbook for Systematic Re-
views of Interventions [22] on five items of bias: (1) se-
lection, (2) performance, (3) detection, (4) attrition, and
(5) reporting. In order to prevent potential reporting
bias, emails and telephone calls were made to the au-
thors of the studies for additional information on the
DM program, were necessary.
Given the likely heterogeneity between studies, we
started with a descriptive analysis of the design, me-
thods, quality, and results of the studies. A reviewer
(MB) extracted data on study characteristics (sample
size, setting, country, follow-up duration and study de-
sign), patient characteristics (age, gender, forced expi-
ratory volume in one second as percentage of the
predicted value (FEV1% pred), history of exacerbations
and smoking status), type and number of interventions
according to the CCM (i.e. self-management), type and
number of healthcare provider(s) involved. Furthermore,
the difference in cost per patient between the DM pro-
gram and the comparator were reported according to
the following categories: 1) DM development, imple-
mentation & operating costs, 2) direct costs of health-
care utilization, 3) direct costs of informal care, 4) direct
non-medical costs borne by patients/families, and 5)
costs of productivity loss. These were checked by a sec-
ond reviewer (AT). The costs were inflated to 2010 [23]
and were converted to Euros (€) by using Dutch pur-
chaser power parities [24]. In addition, we reported the
difference in outcomes which were grouped into the
following categories: 1) care delivery process, 2) patient
behaviour, 3) biomedical, physiological outcomes (e.g.
lung function, body mass index (BMI)), 4) COPD-
exacerbations, 5) health related quality of life and 6)
mortality. Were possible, we have calculated relativerisks for dichotomous outcomes and relative differences
(RD), rate ratio (RR) or standardized mean differences
(SMD) for continuous outcomes. To calculate a weighted
average treatment effect, the data were pooled using a
random-effects meta-analysis model based on the
DerSimonian-Laird method [25] and the example of
Linden and Adams [26]. Heterogeneity in the results
was visually displayed using forest plots grouped into 1)
intervention-, 2) study- and 3) patient characteristics.
Results
Description of studies
The literature search identified 612 potentially eligible
papers and the screening of their references resulted in 6
additional papers. After the first step of selection (based
on title, keywords and abstract) 544 papers were re-
jected. Examining the full text of the remaining papers
led to the exclusion of 56 additional studies. The main
reason for excluding were “no DM program” (n=436).
Lastly, two additional papers were excluded because the
comparator was not usual care or no-intervention. This
resulted in the inclusion of 16 papers reporting 11 diffe-
rent studies. The reasons for excluding initially selected
papers at various stages are presented in a PRISMA dia-
gram [27] (Figure 1).
The selected studies included 7 randomized control
trials (RCT), 2 pre-post and 2 case–control studies
(Table 1). Six studies were conducted in Europe (the
Netherlands (n=3), UK (n=1), France (n=1), Norway
(n=1)) and five studies originated from non-European
countries including USA (n=3), Canada (n=1), New Zea-
land (n=1). The duration of the DM program varied
from 12 to 24 months. Some programs include an inten-
sive phase followed by a maintenance phase; others do
not make this distinction. In those that do, the minimum
duration of the intensive phase was 3 weeks [28][29-31].
The sample size of the intervention group varied from
n=16 [32] to n=524 [33], with a mean sample size of 160
(±168). The sample size of the control group varied
from n=16 [32] to n=371 [34], with a mean sample
size of 95 (±110). The average proportion of drop-out
was 14% (±11).
The average age at baseline was 66(±4) for the inter-
vention and 67(±6) for the control group (Table 1). The
proportion of males varied more widely between studies
with a mean proportion of males of 66% (±19) in the
intervention group and 68% (±17) in the control group.
The mean FEV1% of predicted was 47(±10) in the inter-
vention group and 50(±7) in the control group, which
indicates mild to moderate airflow obstruction according
to the Global Initiative for Chronic Obstructive Lung
Disease (GOLD) guidelines [35]. More than one fourth
of the patients in the studies are smokers, with a mean
proportion of 28(±10) in the intervention and 26(±6) in
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Additional records identified 
through secondary references  
(n =6)
Records after duplicates removed  
(n = 588)
Records screened by title, 
keywords and abstract  
(n = 588)
Records excluded  
(n = 520) Reason:
1. n=24
2. n=415
3. n=61
4. n=20
5. n=0
6. n=0
Full-text articles assessed 
for eligibility 
(n =74)
Full-text articles excluded  
(n = 58) Reason:
1. n=13
2. n=21
3. n=14
4. n=4
5. n=4
6. n=2
Studies included in 
qualitative synthesis
16 papers (=11studies)
Studies included in meta-analysis for:
Health outcomes 14 papers (=11 studies) 
Costs 12 papers (=8 studies)
Exclusion criteria:
1. No COPD
2. No disease management
3. No original empirical research paper
4. Not reported both costs and effects
5. <12 months
6. Comparator is not usual care
Figure 1 In- and exclusion of papers at various stages.
Boland et al. BMC Pulmonary Medicine 2013, 13:40 Page 4 of 17
http://www.biomedcentral.com/1471-2466/13/40the control group. Determining the specific comorbi-
dities of the patients was impossible. However, virtually
all studies excluded patients with significant comor-
bidities. The study and patient characteristics per study
are presented in Table 1.
Various DM interventions were evaluated in the stu-
dies (Table 1). All studies included interventions of the
CCM component self-management support (SMS). Eight
studies evaluated interventions of the component deliv-
ery system design (DSD), followed by decision support
(DEC) (n=7) and clinical information system (CIS) (n=1).
No study included interventions based on the CCM com-
ponents organizational support (ORG) or community
(COM). Two studies included multiple interventions in
one CCM component, three studies included interven-
tions covering two CCM components, five studies covered
three components and one study [36] included inter-
ventions from 4 CCM components. Frequently applied
interventions were (1) patient education on psychosocial
effects of COPD (e.g. dealing with stress arising from liv-
ing with a chronic disease, improving self-efficacy), know-
ledge of COPD and/or self-management skills (e.g. coping
with breathlessness, exercise, encouragement of self-treatment), (2) stimulation of physical activity (e.g. fitness
program in a small group), (3) changes in visits structure
and organization (e.g. follow-up calls in response to ex-
acerbation), (4) individual treatment plan, and (5) exacer-
bation management (e.g. patient training in recognizing
early symptoms of exacerbation, discussion of individual
causes of exacerbations, guidelines for self-treatment of
exacerbations). The frequency of the interventions used in
the included DM programs per CCM component can be
found in Additional file 2.
The number of different professions involved in deliv-
ering of the DM program varied from two to five. One
study did not report which healthcare providers were in-
volved [37]. The most frequently involved healthcare
providers of the DM programs were respiratory/chest
specialist (RS) (90%), respiratory nurse (RN) (90%), gen-
eral practitioner (GP) (70%) and physiotherapist (PHY)
(40%). The intervention characteristics are shown in
Table 1.
The quality of studies and risk of bias
The quality score of the 11 selected studies varied bet-
ween 29% and 80%. The mean score was 59% with a
Table 1 Study-, patient- and intervention characteristics
Study characteristics Patient characteristics Intervention characteristics
Countrya Follow-up
(months)
Study
designb
Sample
size at
baselinec
No of
patients who
completed
studyc
Mean
age
Sex
(% male)
FEV1%
predicted
% with a
history of ≥ 1
exacerbation
in year prior
to study
Smoking
status
(% smokers)
Interventions categories
according to CCM
components*
Professions involved in delivering
of the DM program**
I C I C I C I C I C I C I C SMS DEC DSD CIS Total RS RN GP PHY DIE PHA SW Total
[36] NL 12 Pre-post 317 NA 222 NA 61 NA 56 NA 56 NA NS NS 40 NA ✓ ✓ ✓ ✓ 4 ✓ ✓ ✓ 3
[31] NL 24 RCT 102 97 77 81 66 67 71 71 49 51 1.2 1.0 33 24 ✓ ✓ ✓ 3 ✓ ✓ ✓ ✓ 4
[37] FR 12 RCT 23 22 20 18 65 61 90 78 56 54 NS NS 25 28 ✓ 1 NS NS NS NS NS NS NS NS
[39] USA 12 Case-
control
94 47 NA NA NS NS NS NS NS NS NS NS NS NS ✓ ✓ ✓ 3 ✓ ✓ ✓ 3
[28] NOR 12 RCT 31 31 26 27 57 58 48 52 52 55 NS NS 39 39 ✓ ✓ 2 ✓ ✓ ✓ ✓ ✓ 5
[38] CAN 12 RCT 96 95 86 79 70 69 52 59 45 46 NS NS 25 26 ✓ ✓ ✓ 3 ✓ ✓ ✓ 3
[29] NL 12 RCT 127 121 122 114 65 65 85 84 56 58 1.4 1.3 28 26 ✓ 1 ✓ ✓ 2
[30] UK 24 RCT 61 61 55 49 70 70 49 49 43 49 100e 100 30 20 ✓ ✓ 2 ✓ ✓ 2
[34] USA 12 RCT 372 371 336 323 69 71 98 98 36 38 100 100 22 23 ✓ ✓ ✓ 3 ✓ ✓ ✓ 3
[32] NZ 12 Case-
control
16 16 NA NA 70 75 63 56 26 NSd 100 100 13 19 ✓ ✓ 2 ✓ ✓ ✓ ✓ 4
[33] USA 12 Pre-post 524 NA 349 NA 64 NA 51 NA NS NA NS NA NS NA ✓ ✓ ✓ 3 ✓ ✓ ✓ 3
Total (%) 100 64 73 9 90 90 70 40 10 10 10
a NL Netherlands, FR France, USA United States of America, NOR Norway, CAN Canada, UK United Kingdom, NZ New Zealand, b RCT Randomized Control Trial, c I Intervention, C comparison, d FEV1 Control group
0.72 ± 0.22L, e in the last 4 years; NS Not stated, NA Not applicable, *SMS Self-management support, DEC Decision support, DSD Delivery system design, CIS Clinical information system, **RS Respiratory/chest specialist,
RN Respiratory nurse, GP General practitioner, PHY Physiotherapist, DIE Dietician, PHA Pharmacist, SW Social worker.
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(82%) did not report detailed characteristics of insti-
tution(s) or region in which the intervention is im-
plemented, e.g. size of the region and rural or urban
environment. Only the setting of recruited institution(s) is
known of all studies: 7 in a hospital setting [28-32,37,38],
1 in a primary care setting [36] and 3 in a combination of
a hospital and primary care setting [33,34,39].
Only one study [36] reported a plan to avoid contam-
ination by other interventions and only three studies
clearly provided details of the comparator [31,37,38]. Al-
though all studies scored well on including intermediate
and final health outcomes and costs of healthcare
utilization, the lack of measurement of all relevant costs
and outcome categories decreased the quality score of
most studies.
Selection bias was likely in two studies [32,39] (see
Additional file 4). One study [39] did not report patient-
characteristics, which made it impossible to verify if the
baseline characteristics were comparable. Both studies
[32,39] did not randomly allocate patients. All studies
had a high risk of performance, because blinding of the
intervention for caregivers and patient is impossible. Al-
though blinding of outcome assessors is possible, only 5
studies reported to have done so [28,31,34,37,38]. Four
studies were at risk for attrition bias [32,33,36,39]. These
four studies did not clearly describe the patients that
dropped out from the study in a flow-chart or in the
text. Moreover, one study [33] had a drop-out rate of
33%. Six studies were at risk of selective reporting, be-
cause they did not report statistical difference in costs
and/or outcome [29,30,32-34,38].
Results on costs
Various DM costs were included in the studies. Table 3
shows the results on difference in costs per patient (PP)
between the DM program and the comparator. Of the
11 studies, 5 did not report statistical testing of the cost
difference [29,30,32,33,38] and 1 study [34] reported
only partly which costs differed significantly.
The total difference in costs between the COPD-DM
program and the control group ranged from -€1689 [28]
to €2856 [31], with a mean (±standard deviation (SD))
cost increase of €88 (±€1214). These total costs included
the development, implementation and operating costs,
where reported. Six of the eleven studies (55%) reported
savings in total costs; however no study demonstrated a
significant reduction of the total costs. On the other
hand, no study demonstrated a significant increase of
the total costs either.
The development, implementation and operating costs
varied between €94 [34] and €2976 [38], with a mean
(±SD) costs of €1139 (±€1022). The difference in health-
care costs PP varied between a cost reduction of €2672[32] and a cost increase of €2229 [31]. Nine of the eleven
studies (82%) reported healthcare costs savings, although
the costs significantly decreased in only one of these
studies [39]. The total healthcare costs were mainly
driven by the hospitalization costs. All but one study
[37] reported a reduction in hospitalization costs in
favour of the DM programs. No study estimated the
costs of informal care. Direct-non-medical costs borne
by patients/family were included in two studies. One
study [31] found a decrease in this type of costs of €65
and the other study [28] found a statistically significant
increase in these costs of €47. The productivity costs
were included in three studies: one study [28] showed a
cost reduction of €944 and two studies [29,31] showed
a cost increase of €693 and €280, respectively. These
differences in productivity costs were not statistically
significant.
In total 11 and 9 studies reported total healthcare
utilization and hospital costs, of which 8 and 6 studies
provided enough data to be pooled in a meta-analysis,
respectively. Figure 2a shows the results of the meta-
analysis on healthcare utilization costs. COPD-DM pro-
grams were found to result in average healthcare savings
of €898 PP (95% CI €231-€1566). The heterogeneity in
healthcare costs across studies is large (I2= 93.0%). The
pooled results from the 6 studies that included hospi-
talization costs demonstrated a reduction of €1060 PP
(95% CI €80- €2040) (Figure 2b). However, the hete-
rogeneity between studies in hospital costs is large
(I2= 69.5%).
Table 4 shows the results of the meta-analysis of the
COPD-DM programs by intervention-, study-, and
patient-characteristics. Three intervention-characteristics
were used to define subgroups for the meta-analysis:
CCM components, number of different types of health-
care providers involved in the intervention and duration
of the intervention. When data were pooled by the num-
ber of CCM components, the savings of programs cove-
ring 3 or more CCM components where greater than
those of the programs covering 2 or less components.
This difference was statistically significant for the hos-
pital costs, but not for the total healthcare costs. Like-
wise, greater savings were found for studies with a long
intervention duration (> 12 months), than for studies
with a short intervention duration (< 12 months). These
savings for studies with a long intervention duration
were significant for the hospitalization costs, but not for
the total healthcare costs. Subgroup analysis by number
of professions involved in delivering of the DM program
showed that interventions delivered by 2 or 3 disciplines
of healthcare providers found significant savings in hos-
pital costs as well as total healthcare costs but this was
not found for interventions including 4 or more disci-
plines of healthcare providers.
Table 2 Quality of study
Characteristic Type [36] [31] [37] [39] [28] [38] [29] [30] [34] [32] [33] %
Study population 1. Clear description of in- and exclusion ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ - 91
2. Clear description of drop-outs - ✓ ✓ - ✓ ✓ ✓ ✓ ✓ - - 64
3. The study population consist of an intervention
and control group
- ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ - 82
4. Relevant baseline characteristics are comparable NA ✓ ✓ - ✓ ✓ ✓ ✓ ✓ ✓ NA 89
Intervention 5. Random allocation NA ✓ ✓ - ✓ ✓ ✓ ✓ ✓ - NA 78
6. Clear description of type of intervention ✓ ✓ - ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 91
7. Clear description of the comparator - ✓ ✓ - - ✓ - - - - - 27
8. Detailed characteristics of institution(s)/region in
which the intervention is implemented are described
✓ - ✓ - - - - - - - - 18
9. Co-interventions are avoided ✓ - - - - - - - - - - 9
Measurement of all
relevant cost categories
10. Inclusion of development /implementation /
operating costs
- - - ✓ ✓ ✓ ✓ ✓ ✓ ✓ - 64
11. Inclusion of healthcare utilization costs ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 100
12. Inclusion of direct non-medical and non-direct
costs
- ✓ - - ✓ - ✓ - - - - 27
13. Justification for omitting costs categories - - - - NA ✓ NA - - - - 11
Measurement of all
relevant outcome
categories
14. Healthcare delivery process ✓ - - - ✓ - - - - - - 18
15. Patient behaviour ✓ ✓ ✓ - - - ✓ - - - - 36
16. Biomedical and physiological health outcomes ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 100
17. Health related quality of life and/or mortality
and/or (quality) adjusted life years
✓ ✓ ✓ - - ✓ ✓ ✓ ✓ ✓ ✓ 82
18. Justification of omitting outcome categories NA - ✓ - - - - - - - - 10
Measurement and
valuation of data
19. Perspective explicitly mentioned ✓ ✓ - - ✓ ✓ ✓ - ✓ - - 55
20. The sources of resource utilization are described
and justified
✓ ✓ ✓ - ✓ ✓ ✓ ✓ ✓ ✓ ✓ 91
21. The resource use and costs are reported
separately
- ✓ - ✓ ✓ ✓ - ✓ ✓ ✓ ✓ 73
22.The effects are measured in appropriate units ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 100
23. Data analysis is performed according intention-
to-treat principle
✓ ✓ - - - ✓ ✓ - ✓ - - 45
Presentation of data 24. Allowance made for uncertainty in the estimates
of the costs
✓ ✓ ✓ - ✓ - ✓ - ✓ - - 55
25. Allowance made for uncertainty in the estimates
of the effects
✓ ✓ ✓ ✓ ✓ - ✓ - ✓ - - 64
26. Incremental analysis of costs and effects are
performed
- ✓ - - - - ✓ - - - - 36
Discussion of the
study results
27. The results are interpreted adequate ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 100
28. The results are compared with other studies and
allowances are made for potential differences in
study methodology
✓ ✓ ✓ - ✓ ✓ ✓ ✓ ✓ ✓ - 82
29. The study discusses the generalizability of the
results to other settings and patient groups
✓ ✓ - ✓ - ✓ ✓ - ✓ - - 55
30. The study discusses issues of implementation
of the intervention
✓ ✓ - ✓ - ✓ - - - - - 36
Total quality of study (%) 70 80 60 40 66 70 76 50 67 43 29
NA not applicable.
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Table 3 Results on difference in costs per patient (€ 2010)
Development,
implementation,
operating
Healthcare utilization Informal
care
Direct-non
medical costs
Productivity
loss
Total
Medication Physician
visits
Specialist
visits
Other
outpatient
ED visits Hospitalization Total healthcare
utilization
[36] -47 -47
[31] 6681 -12 -42 20381 -424 22291 -65 693 2856
[37] -507* 1150 652 652
[39] 2007 79 -20982 -2019* -13
[28] 200 -182 -145* -13 -708 -999 47* -944 -1689
[38]# 2976 -22 -2 -158 -2448 -2630 347
[29]# 728 42 -6 -92 -56 280 950
[30]# 94 -79 -79 15
[34]# 545 13 -118 -936* -1042 -497
[32]# 1850 -2004 -2004 -154
[33]# 712 -357 -1804 -2160 -1448
* Significant (p<0.05) ED visit= emergency department visit # no information of significance level available (n=5 studies), Dewan e.a. 2010 [34] reported only information on significance level of hospitalization and
total costs - 1Significantly higher cost: diet nutrition, physiotherapist, dietician, respiratory nurse. 2Costs includes hospitalization, ED visits and Physician visits.
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NOTE: Weights are from random effects analysis
Overall  (I-squared = 93.0%, p = 0.000)
Dewan et al. [34]
Bourbeau et al. [38]
Steuten et al. [36]
Poole et al. [32]
Gallefoss & Bakke [28]
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Figure 2 Pooled results of the meta-analyses on costs. Healthcare utilization costs (a) hospitalization costs (b).
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groups: design, region and quality of study. Savings in
hospital costs as well as total healthcare costs were
found for non-EU countries but not for EU countries.
COPD-DM programs with a non-RCT study design hadon average greater healthcare savings than COPD-DM
programs with a RCT study design. However, the savings
were non-significant for non-RCT studies, whereas there
were significant for RCT studies. Similarly, COPD-DM
programs with a higher quality score found significant
Table 4 Pooled results of the meta-analysis of healthcare costs and hospitalization costs by subgroups
Characteristics Subgroup* Healthcare utilization costs Hospitalization costs
Study (N) Mean difference
(min-max)
Study (N) Mean difference
(min-max)
Intervention CCM 1-2 3 -428 (-1875 to 1018) 3 -311 (-1667 to 1045)
3+ 5 -1047 (-2230 to 137) 3 -1378 (-2609 to -164)
Number of involved healthcare
provider disciplines
2-3 4 -1328 (-2554 to -101) 2 -1674 (-3155 to -192)
4+ 3 -282 (-2510 to 1945) 3 -610 (-1770 to 550)
Intervention duration (months) 0-12 2 -345 (-1986 to 1296) 2 -156 (-1820 to 1508)
12+ 6 -1066 (-2232 to 99) 4 -1406 (-2566 to -246)
Study Design RCT 5 -866 (-1550 to -183)
Non-RCT 3 -1074 (-2945 to 797)
Region EU 4 -168 (-1043 to 706) 3 -323 (-1405 to 758)
Non-EU 4 -1731 (-2507 to -955) 3 -1681 (-3070 to -293)
Quality of study 0-60 3 -872 (-3253 to 1509) 2 806 (-1843 to 3456)
60+ 5 -816 (-1543 to -89) 4 -1266 (-2283 to -250)
Patient Age 0-65 3 -307 (-1195 to 581) 2 -156 (-1820 to 1508)
65+ 4 -1128 (-2694 to 437) 4 -1406 (-2566 to -246)
% male 0-60 4 -929 (-1829 to -29) 3 -1790 (-3180 to -401)
60+ 3 98 (-1568 to 1764) 3 -738 (-1437 to -39)
GOLD 2 4 -168 (-1043 to 706) 3 -323 (-1405 to 758)
3+ 3 -1558 (-2740 to -375) 3 -1681 (-3070 to -293)
Exacerbation Yes 2 -1047 (-1633 to -462) 2 -941 (-1474 to -407)
No** 6 -850 (-1626 to -74) 4 -920 (-2441 to 601)
*If subgroup assignment was impossible, the study was excluded in the meta-analyses.
** Having a history of one or more exacerbations was not stated in the inclusion criteria.
CCM Chronic care model, RCT Randomized control trials, EU European union, GOLD Global initiative for chronic obstructive lung disease.
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whereas studies with a lower quality score did not.
Five patient-characteristics were used to define sub-
groups: age, percentage male, GOLD stage, a history of
exacerbation as inclusion criteria and percentage smo-
kers. Greater savings were found for COPD-DM pro-
grams with older patients, compared to younger patient.
Finally, savings in healthcare costs as well as hospital
costs were higher, when patients were more severely
ill, i.e. had a higher GOLD stage and a history of
exacerbations.
Results on effects
Various DM effects were evaluated in the studies that
reported costs. Of the 11 studies, 1 did not report statis-
tical testing of the effects [32]. Changes in the process of
care delivery were measured in one study, Steuten et al.
[36], which demonstrated a significantly increased pa-
tient satisfaction with a RD of 0.13, indicating that the
patient satisfaction increased by 13%. Changes in pa-
tients’ behaviour (e.g. physical activity, smoking behav-
iour) were measured in five studies. However, it was not
possible to calculate the RR, RD or SMD due to a lackof information [21,29,31,37]. The only study [30] with
complete information on change in patients’ behaviour
showed positive results in favour of DM. In details, the
RD in percentage of smokers was 0.01 and the self-use
of antibiotics and steroids significantly increased with a
RD in percentage of 17.92. Table 5 shows the results on
effects of DM programs in RR, RD or SMD for the other
outcomes.
All studies measured changes in biomedical, physio-
logical health outcomes or exacerbations. Hospitalizations
as a proxy of severe COPD exacerbations were frequently
reported. Two of the three studies that measured six-
minute walk distance (6MWD) [31,37] showed an in-
creased walking distance in the DM group compared to
the usual care group, with the results being statistically
significant in one of these two [37]. Three studies mea-
sured COPD exacerbations: two studies showed an in-
crease of exacerbations [29,31], which was statistically
significant in one study [31], but not in the other [30]. An
exacerbation was defined differently across the three stu-
dies: “an unscheduled need for healthcare, or need for ster-
oid tablets, or antibiotics for worsening of their COPD [30],
a visit to the general practitioner or respiratory physician
Table 5 Results of effects of DM programs
Biomedical, physiological health outcomes
and exacerbations
Health related
quality of life
Relative Risk of mortality
[36] RD RD
• Fev1% predicted= -0.02 • SGRQ= -0.03
• Fev1 reversibility= -0.27 • VAS= 0.03*
• Tiffeneau index= 0.02
[31] RR SMD • 1.01(0.30-3.37)
• Hospitalization= 0.78 (0.69-0.89) • SGRQ=-0.15*
• VAS= 1.01
• Exacerbations= 1.39 (1.10-1.74) • EQ-5D= 0.17
SMD
• MRC= 0.58*
• 6MWD= 0.30
• Endurance time=0.37*
• Handgrip force= 0.24
• PI max= 0.29
• BMI= -1.22
• Fev1% predicted= -0.13
[37] SMD SMD
• 6MWD= 0.99* • SGRQ= 0.01
• Peak work rate=-0.88 • VAS=-0.07
• Peak Vo2= -0.06
• Energy= -0.30*
• Pain= 0.20
• Emotional reaction= -0.90*
• Sleep= 3.62
• Isolation= -0.40
• Physical mobility=0.18
• Voorrips total= 1.27*
[39] RR
• Hospitalization= 0.35 (0.29-0.43)
• ED visits= 0.39 (0.33-0.45)
[28] RR
• Days in hosp= 0.28 (0.24-0.32)
• Absenteeism from work= 0.05 (0.03-0.09)
[38]# RR SMD • 0.55 (0.19-1.58)
• Hospitalization= 0.54(0.48- • SGRQ= -0.29*
• 0.61)*
• Hospitalization 1 or more= 0.64(0.45-.91)*
• ED visits=0.64 (0.53-0.78)*
• ED visit 1 or more= 0.64(0.48-0.86)*
SMD
• Fev1=0.00
• FVC=0.00
[29]# SMD SMD • 0.95 (0.20-4.63)
• 6MWD= -0.09 • SGRQ= -0.03
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Table 5 Results of effects of DM programs (Continued)
[30]# RR • 0.50 (0.20-1.25)
• Hospitalization= 1.20 (1.04-1.38) due to COPD=0.13 (0.02-0.97)*
• Hospitalization 1 or more= 1.08 (0.74-1.57)
• Exacerbation 1 or more= 1.00 (0.87-1.15)
[34]# RR • 0.75 (0.50-1.13)
• Hospitalization= 0.72 (0.65-0.79)*
• ED visits=0.73 (0.68-0.79)*
[32]# RR • 0.33 (0.04-2.87)
• Hospitalization= 1.72 (1.02-2.90)
• Hospitalization 1 or more = 1.08 (0.75-1.57)
[33]# RD RD
• Hospitalization=-0.53 • SGRQ=-0.04
• ED visits=-0.66
• ICU admission=-0.57
• Absenteeism from work= -0.77
* Significant (p<0.05) - SGRQ St. George's respiratory questionnaire, VAS Visual analogue scale, FEV1%pred % predicted forced expiratory volume in 1 second,
FEV1 Rev Forced expiratory volume in 1 second reversibility, MRC Medical research council dyspnoea scale, 6MWD= Six-minute walk distance, EQ-5D EuroQoL 5
dimensions, PImax Maximal inspiratory mouth pressure, Peak VO2 Peak oxygen uptake mL-1 kg-1 min-1, BMI Body mass index, ED visits Emergency department
visits, FVC Forced vital capacity, Days in hosp= Days in hospital, ICU admission Intensive care unit admission.
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prednisolone or a visit to the emergency department or day
care of a hospital, which according to the patient, was re-
lated to a COPD exacerbation[31], worsening of respira-
tory symptoms that required treatment with a short course
of oral corticosteroids or antibiotics, as judged by the pa-
tient in the self-treatment group or by the study physician
in the intervention and control groups[29].” Complete in-
formation on the RR of hospitalization was available for 6
of the 11 studies. Meta-analysis shows that DM programs
decreased hospitalizations, but the RR was not significant
(RR, 0.75, 95% CI, 0.54-1.03) (Figure 3a).
Changes in health related quality of life were described
in 6 studies, which all used the SGRQ. Five of the six
studies (83%) demonstrated an improved quality of life
in favour of DM (Figure 3b), which was statistically sig-
nificant in two studies [8,31,38]. The pooled results of
the SGRQ showed a small significant reduction of the
SGRQ in favour of DM (1.7 95% CI: 0.5 to 2.9). This re-
duction does not exceed the clinical relevant improve-
ment of four points [40]. In addition to the SGRQ, three
studies measured the health-related quality of life on a
Visual Analogue Scale (VAS) and one study measured
the EuroQol 5 dimensions (EQ-5D). Two studies [31,36]
reported an increase in VAS in favour of DM and one
study [37] showed a small decrease in VAS in favour of
usual care. The one study [36] with significantly different
results in the VAS showed a small increase (RD=0.03).
The number of patients that died during the study was
described in 6 studies. Mortality never differed signifi-
cantly between groups in individual studies, however thepooled Relative Risk showed a small significant re-
duction in all-cause mortality (0.70, 95% CI 0.51-0.97)
(Figure 3c).
Discussion
We systematically reviewed the impact of COPD-DM
programs on both healthcare costs and health outcomes
and highlighted the variations in intervention-, study-,
and patient-characteristics.
The meta-analysis showed that DM led to average sav-
ings in healthcare costs of €898 PP (95% CI: €231 to
€1566), hospitalization costs of €1060 PP (95% CI: €80
to €2040) and a decreased rate ratio of hospitalizations
(0.75, 95% CI, 0.54-1.03). The costs of developing, im-
plementing and operating the program were excluded
from this estimate. Therefore, the results need to be
interpreted with caution as the inclusion of all relevant
costs could result in much lower cost savings, or even a
total cost increase. Overall, six of the eleven studies
reported savings on the total costs (including operating
costs and non-medical costs), with a mean (±SD) costs
increase of €88 (±1214). Interestingly, 6 studies did not
report significance testing for the total costs and the
remaining 5 studies did not demonstrate a significant re-
duction of the total costs.
The meta-analysis showed that the mean hospital costs
savings (€1060 PP) were larger than the mean healthcare
utilization savings (€898 PP). This is not caused by includ-
ing different studies in the meta-analyses. It is also not un-
usual because a DM program initiates a more intensive
treatment of the patient, often in primary or outpatient
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Figure 3 Pooled results of the meta-analyses on health outcomes. Rate Ratio of hospitalization (a) difference in SGRQ (b) Relative Risk of
mortality (c).
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reduce the length of hospital stay. The more intense treat-
ment leads to a cost increase, the prevention of admis-
sions to cost savings, so overall savings in total healthcare
costs are lower than savings in hospital costs.
Results of the quality assessment showed that the
studies scored between 29 and 80, with a mean of 59. The
studies that scored the lowest on our quality-instrument
also had a substantial risk of bias [32,33,39]. Only 6 of the
eleven studies (55%) scored more than 60 points. Studies
with a lower quality score showed smaller savings in
healthcare costs. This is related to the difference between
RCTs and non-RCTs, where the first showed smaller but
significant savings, whereas the latter showed greater but
non-significant changes. The main problem in the meth-
odological quality of the studies seems to be the lack of
measuring all relevant costs and outcome categories, no
clear description of the comparator or a description of the
institution(s)/region in which the intervention was im-
plemented. This complicates the interpretation of the
study results. When trying to explain why results are dif-
ferent across studies, differences in patient characteristics
are important. We found indications that DM led to
greater savings in older patients, patients with a higher
GOLD stage of airflow obstruction, and patients with a
history of exacerbations. As these patients make more
use of health care services, there is more room for
cost savings.
Differences between intervention characteristics were
also important. In line with previous reviews we found
that patients who received 2 [6] or even 3 or more [4,8]
interventions within different CCM components in DM
programs for COPD had lower rates of hospitalizations.
Consequently, savings in healthcare costs were also grea-
ter. Similarly, studies with a longer duration of follow-up
showed greater reductions in hospital costs, because the
relatively low frequency of hospital admissions requires a
sufficiently long follow-up time to detect a reduction.
The aim of this review was to investigate the relation
between the impact of COPD-DM programs on costs
and their impact on health outcomes. Because costs and
outcomes can only be related when they are obtained
within the same study, we investigated the health out-
comes that were reported in the papers reporting cost
consequences of DM programs. Cost-effectiveness stu-
dies commonly relate costs to effects and calculate the
addition costs per unit of additional effect (incremental
cost-effectiveness ratio). However, there were only two
studies reporting cost-effectiveness ratios [29,31]. There-
fore, we had to review costs separately from the effects
that were reported in the same studies.
There was a great variability in the type of outcome
measures that were reported. Most DM programs led to
changes in care delivery, as interventions to promoteevidence based clinical care (e.g. education of healthcare
provider, integration of specialist expertise in primary
care) and interventions to promote effective, efficient
care (e.g. systematic and pro-active follow-up of pa-
tients) were frequently provided as part of the DM pro-
gram. Biomedical or physiological health outcomes and
health related quality of life have shown small but posi-
tive changes in favour of DM. The quality of life results
are in line with previous reviews. Niesink et al. [7] also
demonstrated positive results of DM on quality of life in
people with COPD. There was a lack of evidence on
whether DM programs lead to changes in patient behav-
iour, although all studies provided interventions to em-
power and prepare patients to manage their disease (e.g.
exacerbation management, individual treatment plan).
This was also found in previous reviews [6,8].
Contrary to the positive biomedical or physiological
outcomes, it is somewhat surprising that some studies
found comparable [30] or even higher exacerbation rates
for DM than for usual care [29,31]. Self-management
training of the patients could have reduced the problem
of under-reporting of exacerbations due to an improved
ability of patients to recognize an exacerbation. DM
programs could also have led to earlier detection of
an exacerbation because of more frequent scheduled
caregivers contacts [29,31].
Five previous systematic reviews investigated the ef-
fects of COPD-DM programs on health outcomes [4-8].
The results of COPD-DM programs on quality of life in
these reviews were similar to our study. In more de-
tail, 50% of the studies in the review of Niesink et al.
[7], 67% of the studies in the review of Peytemann-
Brideveaux [5] and 53% of the studies in the review of
Steuten et al. [8] have shown statistically significant posi-
tive outcomes of COPD-DM on one or more domains of
the quality of life instruments. The two studies that
pooled data on the SGRQ demonstrated small but posi-
tive results in the DM group as compared to the control
group. These results were statistically significant in the re-
view by Lemmens et al. [4] (−2.52, 95% CI: -5.00, -0.05)
and not statistically significant in the review by Adams
et al. [6] (−0.25, 95% CI: -1.74, 1.24). Our pooled estimate
of the improvement in SGRQ due to DM was −1.7
(95% CI: -2.9, -0.5). The effects of COPD-DM programs
on mortality were estimated in two meta-analyses [5,6].
Both studies found lower mortality rates in the DM group,
but the difference with the control group was not statisti-
cally significant. Our RR of 0.7 (95% CI: 0.51, 0.97) further
supports the positive results of COPD-DM on all-cause
mortality. Furthermore, the effect of COPD-DM on hos-
pitalization was examined in two reviews. The odds ratio
of hospitalization in the study of Lemmens [4] was 0.58
(95% CI: 0.40-0.83) and the relative risk in the study of
Adams [6] was 0.79 (95% CI: 0.66-0.94) which are
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our study.
All studies in our review evaluated a mixed package of
interventions. Determining the contribution of individual
components of this package is impossible. Patient educa-
tion on self-management was frequently included in the
DM programs, most often in combination with changes in
visit structure and stimulation of physical activity. Surpris-
ingly few DM programs focused on structural smoking
cessation support or nutritional therapy, i.e. only one DM
program involved dieticians [31]. Overall, the categoriza-
tion of the DM interventions based on the CCM compo-
nents showed that all studies included interventions
within the self-management support (SMS) component
and none within the organizational support (ORG) or
community (COM) components. However, these compo-
nents are essential to support the structural implementa-
tion of a large DM program. It is likely that these studies
did not explicitly address these components because of
the relatively small-scale on which the programs were
implemented or because the organizational, financial and
societal conditions necessary to implement disease man-
agement were already in place.
COPD-DM programs have much in common with re-
habilitation programs. We avoided the inclusion of these
programs by excluding all studies that evaluated a short
(usually 1–4 months), intensive, multidisciplinary pro-
gram, in which exercise training (both muscle training
and endurance training) was the main component, be-
cause DM aims to change the routine of care delivery
for a prolonged period of time. However, stimulating
physical exercise is an element of many DM programs
and some programs e.g. [29,37] pay more attention to
this than others. Also, some interventions start with a
short intensive intervention phase, followed by a longer
and less intensive maintenance phase e.g. [30,31]. The
first part may resemble pulmonary rehabilitation
whereas the latter part is clearly long-term DM. Because
of this sliding scale it is sometimes difficult to make a
clear distinction between a low-intensity community-
based pulmonary rehabilitation program and an inten-
sive DM program.
There are several limitations of this study. Firstly, most
studies demonstrate a lack of data on other cost then
the cost of healthcare utilization. The importance of
these other costs is shown in the study of Hoogendoorn
et al. [31] and Monninkhof et al. [29] where including
productivity costs led to increased costs for the DM pro-
gram. The study by Hoogendoorn et al. [31] also was the
only study that included total healthcare costs irrespect-
ive of the reason of resource use whereas other studies
included COPD-related healthcare costs. In addition, only
two studies reported the incremental cost-effectiveness ra-
tio of the DM program [29,31].Secondly, we pooled the results of the DM programs
despite the large heterogeneity. This heterogeneity is pri-
marily due to the variety of different interventions in-
cluded in a DM programs, the variety of study designs
and the quality of the studies, and the variety of patient
characteristics. We address this by conducting subgroup
analysis by study-, intervention-, and patient characteris-
tics. All across Europe, reimbursement decision makers
face the difficult question whether or not to reimburse
such programs on a wide scale. Theoretically, the poten-
tial savings of these DM programs are great, but the evi-
dence for this is still quite sketchy. We believe we can
give some guidance by bringing all this evidence together,
discuss its quality, combine it into the best possible esti-
mate of potential savings we can currently get, and try to
identify patient- and intervention-characteristics that may
contribute to greater savings.
Finally, the generally small proportion of COPD pa-
tients that was included in COPD-DM programs [41,42]
may jeopardize the generalizability of the costs and
effects of DM programs. The exclusion of COPD pa-
tients with multi-comorbidities will decrease the gene-
ralizability of the results to the entire population of
COPD patients in which comorbidity is frequent. For
instance, studies excluded patients suffering from any
“serious” [29,37], “overwhelming” [32] or “significant”
[30] comorbidities.
Conclusions
This systematic review of the literature suggests that
COPD-DM programs reduce hospital admissions and
decrease hospital and total healthcare costs (excluding
development and management costs of DM programs).
They also improve health outcomes, including health-
related quality of life. Results are however quite he-
terogeneous, varying by study-, intervention-, and
disease-characteristics. Designers and managers of DM
programs for chronic diseases can use this information to
develop and target DM programs to maximise their cost-
effectiveness. Future economic evaluations of DM pro-
grams should target a wider population of COPD-patients
and be of higher methodological quality.
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